2-Pyrrolidone → (R)-4-(1-cyclopropylethylamino)-6-(2-oxopyrrolidin-1-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide
반응식
Br[C:2]1[CH:3]=[C:4]2[C:9]([NH:10][C@@H:11]([CH:13]3[CH2:15][CH2:14]3)[CH3:12])=[C:8]([C:16]([NH2:18])=[O:17])[CH:7]=[N:6][N:5]2[CH:19]=1.[NH:20]1[CH2:24][CH2:23][CH2:22][C:21]1=[O:25]>>[CH:13]1([C@H:11]([NH:10][C:9]2[C:4]3[N:5]([CH:19]=[C:2]([N:20]4[CH2:24][CH2:23][CH2:22][C:21]4=[O:25])[CH:3]=3)[N:6]=[CH:7][C:8]=2[C:16]([NH2:18])=[O:17])[CH3:12])[CH2:15][CH2:14]1참가 물질
3
실험 절차
Example 185 was prepared from 6-bromo-4-(((1R)-1-cyclopropylethyl)amino)-pyrrolo[1,2-b]pyridazine-3-carboxamide (Intermediate 4) and 2-pyrrolidinone according to the procedure described for Example 37. HPLC (condition G): retention time=7.10 min. LCMS (ES+) m/z: 328.1.
출처 및 근거
- ORD 기록
- ord-a54a958ae632483b867b5305c5c3b142
- 출처 데이터셋
- uspto-grants-2015_12
- DOI